Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.3 USD | +1.34% | +6.29% | -20.42% |
05-02 | Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed | MT |
05-02 | Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.42% | 19.01B | |
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B | |
+19.33% | 11.45B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals : UBS Adjusts Price Target on Alnylam Pharmaceuticals to $129 From $122, Maintains Neutral Rating